Compare Eli Lilly And Co (LLY) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Thomson Reuters Corp — how do they compare? Eli Lilly And Co trades at $1,206.28 (market cap $1.08T), while Thomson Reuters Corp trades at $103.75 (market cap $45.38B). The key difference: Eli Lilly And Co is far larger — about 23.8× Thomson Reuters Corp's market cap, and Thomson Reuters Corp pays the higher dividend (2.5%). Which is the better fit depends on your goals.
| LLY | TRI | |
|---|---|---|
Market Cap | $1.08T | $45.38B |
Sector | Health | Industrials |
52-Week High | $1.24K | $178.77 |
52-Week Low | $639.43 | $76.55 |
Enterprise Value | $1.13T | $48.00B |
Dividend Yield | 0.57% | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.
Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.
Thomson Reuters (TRI) trades at $104.36, up 2.48% today, with a bullish technical signal and strong support at $102. The company reported Q2 2026 earnings of $0.99 per share, beating estimates, and raised full-year revenue guidance. Fundamentals show robust profitability with a 21.22% net income margin and 8% organic revenue growth, though cash flow trends indicate recent net outflows.
Outlook remains positive driven by AI product adoption and recurring revenue growth, but risks include execution on tech transitions and competitive pressures. Analysts project a 29.8% upside to the $124 high target, with a majority recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
